ID
33107
Descrição
Study ID: 104021 Clinical Study ID: 104021 Study Title: A phase III, partially blind, randomized study to evaluate the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ Tritanrix™-HepB and GSK Biologicals Kft’s DTPw-HBV vaccines as compared to concomitant administration of Commonwealth Serum Laboratory’s (CSL’s) DTPw (Triple Antigen™) and GSK Biologicals’ HBV (Engerix™-B), when co-administered with GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine, to healthy infants at 3, 4½ and 6 months of age, after a birth dose of hepatitis B vaccine. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00158756 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: Hepatitis B Vaccine, Recombinant Trade Name: Engerix B Study Indication: Hepatitis B
Palavras-chave
Versões (1)
- 28/11/2018 28/11/2018 -
Titular dos direitos
GSK group of companies
Transferido a
28 de novembro de 2018
DOI
Para um pedido faça login.
Licença
Creative Commons BY-NC 3.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Immunogenicity of co-administration of Tritanrix™-HepB and DTPw-HBV vaccines or Triple Antigen™ and Engerix™-B with HRV vaccine to infants (3, 4½ and 6 month) - 104021
Contraindications to Subsequent Vaccination
- StudyEvent: ODM
Descrição
DTPw vaccines
Descrição
GSK Biologicals' RotarixTM vaccine or its placebo
Descrição
Local registered OPV
Descrição
Relative Contraindications
Descrição
If any one of these AEs occurs at the time scheduled for vaccination, the subject may be vaccinated at a later date, within the time window specified in the protocol, or withdrawn at the discretion of the investigator. The subject must be followed until resolution of the event, as with any AE.
Tipo de dados
text
Descrição
DTPw vaccines
Descrição
GSK Biologicals' RotarixTM or its placebo
Descrição
Precautions for DTPw vaccines
Descrição
If any of the following events occur in temporal relation to receipt of the study vaccines, the decision to give subsequent doses of vaccine containing the pertussis component should be carefully considered. The following event were previously considered contraindications and are now considered precautions by the Advisory Committee on Immunization Practices (ACIP)
Tipo de dados
text
Descrição
DTPw-HBV vaccines should under no circumstances be administered intravenously
Similar models
Contraindications to Subsequent Vaccination
- StudyEvent: ODM